Revenues Tell The Story For Ambu A/S (CPH:AMBU B) As Its Stock Soars 27%

Ambu A/S (CPH:AMBU B) shareholders would be excited to see that the share price has had a great month, posting a 27% gain and recovering from prior weakness. Taking a wider view, although not as strong as the last month, the full year gain of 17% is also fairly reasonable.

Even after such a large jump in price, it's still not a stretch to say that Ambu's price-to-sales (or "P/S") ratio of 6.7x right now seems quite "middle-of-the-road" compared to the Medical Equipment industry in Denmark, where the median P/S ratio is around 6.6x. Although, it's not wise to simply ignore the P/S without explanation as investors may be disregarding a distinct opportunity or a costly mistake.

View our latest analysis for Ambu

ps-multiple-vs-industry
CPSE:AMBU B Price to Sales Ratio vs Industry January 12th 2025
Advertisement

What Does Ambu's Recent Performance Look Like?

Ambu certainly has been doing a good job lately as it's been growing revenue more than most other companies. Perhaps the market is expecting this level of performance to taper off, keeping the P/S from soaring. If not, then existing shareholders have reason to be feeling optimistic about the future direction of the share price.

Keen to find out how analysts think Ambu's future stacks up against the industry? In that case, our free report is a great place to start.

What Are Revenue Growth Metrics Telling Us About The P/S?

Ambu's P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.

Taking a look back first, we see that the company managed to grow revenues by a handy 13% last year. This was backed up an excellent period prior to see revenue up by 34% in total over the last three years. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.

Turning to the outlook, the next three years should generate growth of 12% each year as estimated by the eight analysts watching the company. That's shaping up to be similar to the 10% each year growth forecast for the broader industry.

With this in mind, it makes sense that Ambu's P/S is closely matching its industry peers. Apparently shareholders are comfortable to simply hold on while the company is keeping a low profile.

What Does Ambu's P/S Mean For Investors?

Ambu's stock has a lot of momentum behind it lately, which has brought its P/S level with the rest of the industry. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

Our look at Ambu's revenue growth estimates show that its P/S is about what we expect, as both metrics follow closely with the industry averages. At this stage investors feel the potential for an improvement or deterioration in revenue isn't great enough to push P/S in a higher or lower direction. All things considered, if the P/S and revenue estimates contain no major shocks, then it's hard to see the share price moving strongly in either direction in the near future.

It is also worth noting that we have found 2 warning signs for Ambu that you need to take into consideration.

If strong companies turning a profit tickle your fancy, then you'll want to check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About CPSE:AMBU B

Ambu

Researches, develops, manufactures, markets, and sells medical technology solutions in North America, Europe, and internationally.

Flawless balance sheet with solid track record.

Advertisement

Weekly Picks

TA
Talos
TSLA logo
Talos on Tesla ·

The "Physical AI" Monopoly – A New Industrial Revolution

Fair Value:US$665.3635.6% undervalued
24 users have followed this narrative
14 users have commented on this narrative
16 users have liked this narrative
MA
CSG logo
Marek_Trnka on CSG ·

Czechoslovak Group - is it really so hot?

Fair Value:€5547.3% undervalued
34 users have followed this narrative
1 users have commented on this narrative
13 users have liked this narrative
AL
alex30free
SECARE logo
alex30free on Swedencare ·

The Compound Effect: From Acquisition to Integration

Fair Value:SEK 46.2850.2% undervalued
9 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

CO
composite32
TTE logo
composite32 on TotalEnergies ·

This strategic transformation of TTE? Significant re-rating potential

Fair Value:€68.56.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MA
MarkoVT
5253 logo
MarkoVT on COVER ·

Q3 Outlook modestly optimistic

Fair Value:JP¥1.58k2.1% undervalued
10 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MI
Minesweeper
6125 logo
Minesweeper on Okamoto Machine Tool Works ·

Okamoto Machine Tool Works focus on profitability

Fair Value:JP¥6.91k35.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OO
NEO logo
OOO97 on Neo Performance Materials ·

Undervalued Key Player in Magnets/Rare Earth

Fair Value:CA$25.3317.2% undervalued
78 users have followed this narrative
0 users have commented on this narrative
20 users have liked this narrative
DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.887.7% undervalued
57 users have followed this narrative
5 users have commented on this narrative
25 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$603.2233.0% undervalued
1267 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative

Trending Discussion

Advertisement